Royalty Pharma Plc
(NASDAQ : RPRX)

... ...
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.13%163.560.7%$1160.35m
PFEPfizer Inc. 0.19%36.550.9%$1138.06m
LLYEli Lilly & Co. 1.95%206.301.1%$934.48m
ABBVAbbVie, Inc. -0.34%110.881.9%$732.28m
BMYBristol-Myers Squibb Co. 0.61%64.571.0%$679.31m
MRKMerck & Co., Inc. -0.26%80.970.7%$677.96m
AZNAstraZeneca Plc 1.33%53.251.2%$669.74m
ARCTArcturus Therapeutics Holdings, Inc. 6.16%67.700.0%$229.98m
GRTSGritstone Oncology, Inc. 6.11%27.110.0%$211.05m
VTRSViatris, Inc. 0.69%17.430.0%$193.56m
RPRXRoyalty Pharma Plc 1.47%51.160.2%$174.27m
NVSNovartis AG 0.06%96.940.2%$174.04m
GSKGlaxoSmithKline Plc 1.54%38.360.2%$154.42m
SNYSanofi 0.10%49.690.2%$134.98m
RGENRepligen Corp. 1.11%219.326.9%$78.39m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.